The US Food and Drug Administration announced in an Aug. 20, 2009 release that it would like to amend postmarket safety reporting regulations "to require that manufacturers and other facilities subject to current reporting requirements submit their reports in an electronic format."
The US Food and Drug Administration announced in an Aug. 20, 2009 release that it would like to amend postmarket safety reporting regulations “to require that manufacturers and other facilities subject to current reporting requirements submit their reports in an electronic format.”
One of two new proposed rules affecting drugs and biologics asks companies to submit adverse experience reports electronically so that the agency can process, review, archive, and retrieve critical information in a more efficient and effective way. The types of adverse events that must be reported remain the same. The second proposed rule applies to adverse events for medical devices.
Currently, reports are submitted on paper and entered into the FDA system manually. “Both proposed rules will improve the agency’s ability to obtain safety information more quickly, which will help lead to faster identification of potential safety problems. Information obtained from these reports may be critical to future action that improves patient safety,” said David Buckles, Ph.D., director of the Division of Postmarket Surveillance at the FDA’s Center for Devices and Radiological Health (CDRH), in the release.
The agency’s Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research began a pilot program in 2000 to allow manufacturers to submit electronic adverse event reports through FDA’s Electronic Submission Gateway or on CD-ROM, digital tape, or floppy disk. The International Conference on Harmonization (ICH M4) defines standards for these submissions. Under the proposed rule for drugs and biologics, firms will be able to submit electronic reports using ICH standards or through a new safety reporting Web portal that FDA is developing. Firms that wish to use the gateway will need to obtain an electronic certificate from the agency first.
Not covered in the proposed rule for drugs and biologics are: “safety reports filed under an investigational new drug application, annual reports that manufacturers submit to FDA on approved drugs and biologics, biologic product deviation reports, reports of complications of blood transfusion and collection confirmed to be fatal, and certain reports on human cells, tissues and cellular and tissue-based products.”
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.